TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis

NASDAQ:TMDX • US89377M1099

131.85 USD
-5.93 (-4.3%)
At close: Feb 25, 2026
133 USD
+1.15 (+0.87%)
After Hours: 2/25/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

TMDX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. TMDX has only an average score on both its financial health and profitability. TMDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year TMDX was profitable.
  • TMDX had a positive operating cash flow in the past year.
  • In the past 5 years TMDX reported 4 times negative net income.
  • In the past 5 years TMDX reported 4 times negative operating cash flow.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.70%, TMDX belongs to the top of the industry, outperforming 92.97% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 25.84%, TMDX belongs to the top of the industry, outperforming 96.76% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 8.75%, TMDX belongs to the best of the industry, outperforming 88.11% of the companies in the same industry.
Industry RankSector Rank
ROA 9.7%
ROE 25.84%
ROIC 8.75%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • The Profit Margin of TMDX (16.20%) is better than 93.51% of its industry peers.
  • TMDX has a Operating Margin of 16.94%. This is amongst the best in the industry. TMDX outperforms 88.11% of its industry peers.
  • Looking at the Gross Margin, with a value of 60.28%, TMDX is in the better half of the industry, outperforming 62.70% of the companies in the same industry.
  • TMDX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 16.94%
PM (TTM) 16.2%
GM 60.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
  • TMDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 5.82 indicates that TMDX is not in any danger for bankruptcy at the moment.
  • TMDX has a Altman-Z score of 5.82. This is amongst the best in the industry. TMDX outperforms 80.54% of its industry peers.
  • TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 4.24, TMDX is doing good in the industry, outperforming 80.00% of the companies in the same industry.
  • TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
  • TMDX has a worse Debt to Equity ratio (1.43) than 78.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 4.24
Altman-Z 5.82
ROIC/WACC0.92
WACC9.52%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 7.69 indicates that TMDX has no problem at all paying its short term obligations.
  • TMDX's Current ratio of 7.69 is amongst the best of the industry. TMDX outperforms 88.11% of its industry peers.
  • A Quick Ratio of 7.13 indicates that TMDX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 7.13, TMDX belongs to the top of the industry, outperforming 89.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.69
Quick Ratio 7.13
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 182.18%, which is quite impressive.
EPS 1Y (TTM)182.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.18%

3.2 Future

  • TMDX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.46% yearly.
  • Based on estimates for the next years, TMDX will show a quite strong growth in Revenue. The Revenue will grow by 17.03% on average per year.
EPS Next Y3.67%
EPS Next 2Y13.05%
EPS Next 3Y15.63%
EPS Next 5Y10.46%
Revenue Next Year20.55%
Revenue Next 2Y19.08%
Revenue Next 3Y17.02%
Revenue Next 5Y17.03%

3.3 Evolution

TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 46.26, the valuation of TMDX can be described as expensive.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than the industry average as 69.73% of the companies are valued more expensively.
  • TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.05.
  • A Price/Forward Earnings ratio of 44.63 indicates a quite expensive valuation of TMDX.
  • Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than 67.03% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (28.03), we can say TMDX is valued expensively.
Industry RankSector Rank
PE 46.26
Fwd PE 44.63
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 67.03% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 75.68% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.36
EV/EBITDA 39.07
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TMDX does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as TMDX's earnings are expected to grow with 15.63% in the coming years.
PEG (NY)12.6
PEG (5Y)N/A
EPS Next 2Y13.05%
EPS Next 3Y15.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TMDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRANSMEDICS GROUP INC

NASDAQ:TMDX (2/25/2026, 8:00:01 PM)

After market: 133 +1.15 (+0.87%)

131.85

-5.93 (-4.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners111.19%
Inst Owner Change-1.81%
Ins Owners2.95%
Ins Owner Change1.67%
Market Cap4.51B
Revenue(TTM)N/A
Net Income(TTM)91.77M
Analysts83
Price Target148.92 (12.95%)
Short Float %23.79%
Short Ratio11.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)0.06%
PT rev (3m)-0.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.04%
EPS NY rev (1m)0%
EPS NY rev (3m)0.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.08%
Valuation
Industry RankSector Rank
PE 46.26
Fwd PE 44.63
P/S 7.95
P/FCF 37.36
P/OCF 25.26
P/B 12.68
P/tB 13.19
EV/EBITDA 39.07
EPS(TTM)2.85
EY2.16%
EPS(NY)2.95
Fwd EY2.24%
FCF(TTM)3.53
FCFY2.68%
OCF(TTM)5.22
OCFY3.96%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)12.6
PEG (5Y)N/A
Graham Number25.82
Profitability
Industry RankSector Rank
ROA 9.7%
ROE 25.84%
ROCE 11.08%
ROIC 8.75%
ROICexc 18.94%
ROICexgc 19.61%
OM 16.94%
PM (TTM) 16.2%
GM 60.28%
FCFM 21.29%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 4.24
Debt/EBITDA 4.16
Cap/Depr 224.51%
Cap/Sales 10.19%
Interest Coverage 250
Cash Conversion 146.57%
Profit Quality 131.41%
Current Ratio 7.69
Quick Ratio 7.13
Altman-Z 5.82
F-Score7
WACC9.52%
ROIC/WACC0.92
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)182.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y3.67%
EPS Next 2Y13.05%
EPS Next 3Y15.63%
EPS Next 5Y10.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.18%
Revenue Next Year20.55%
Revenue Next 2Y19.08%
Revenue Next 3Y17.02%
Revenue Next 5Y17.03%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 4 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 3 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Overvalued.


How profitable is TRANSMEDICS GROUP INC (TMDX) stock?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.


How financially healthy is TRANSMEDICS GROUP INC?

The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.